Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #47 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets. Emcure expects low to mid-teen revenue growth in FY27 and beyond.
From Emcure Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets.
- Domestic market expected to grow faster than industry (~8-9%) at low double-digits, supported by strong teams and portfolios in cardio-diabetes, biologics, women's health, and new initiatives.
- International markets (Europe, Canada, Emerging markets) expected to maintain strong growth, with Europe's business projected for mid-teens CAGR over the next 2 years. Amphotericin B launch is a key growth driver.
- Growth levers include ramp-up of semaglutide partnership, dermal product Emcutix, consumer business Arth, and new launches.
2 more points from Emcure Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY27, Emcure Pharmaceuticals plans a capital expenditure (capex) of approximately INR 400-425 crores.
- The company continues to invest in R&D, with FY26 R&D investments at INR 383.5 crores (4.2% of revenue), supporting pipeline development in complex injectables, biosimilars, novel delivery routes, and Antibody Drug Conjugates (ADC).
- Strategic investments include in-licensing deals (e.g., partnership with Novo Nordisk for Poviztra, expanded partnership with Sanofi for Amaryl & Cetapin, and distribution agreement with Roche for nephrology drugs).
2 more points from Emcure Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Emcure's non-ARV business, which is crucial for revenue diversification, maintains a strong order book.
- The HIV segment continues to enjoy a pole position with a robust ARV order book.
- The company has ongoing registrations in various markets supporting this strong order book.
2 more points from Emcure Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.5K Cr, net profit ₹244 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q4 FY26 results?
Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets. Emcure expects low to mid-teen revenue growth in FY27 and beyond.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.3 with a market cap of ₹37,158 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
For FY27, Emcure Pharmaceuticals plans a capital expenditure (capex) of approximately INR 400-425 crores.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.